ALT Company Profile and Key Details

ALT has shown sold momentum, gaining 4.44% over the past week and 10.44% over the past quarter, though year-to-date performance is up 17.17%. Short-term trend indicators are bearishly aligned (SMA20 -6.74%, SMA50 -2.25%, SMA200 -1.26%). The stock’s 14-day RSI is 43.9 (neutral), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -42.3% below its high and over 53.79% above its low. Average 10-day trading volume of 7.19 million shares is significantly above the 3-month average of 3.94 million, indicating heightened recent market interest.

Altimmune, Inc. has 130.11 million shares outstanding. The public float is 129.15 million shares, elevated short interest at 22.52% of float. This equals 29.25 million shares. The short ratio is 8.11 days. Institutional investors hold 40.7% of the float. Insiders own 0.67%. PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. holds 6.63 million shares, Venrock Healthcare Capital Partners III, L.P. has 4.50 million shares and VELOCITY PHARMACEUTICAL HOLDINGS LLC has 1.69 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Altimmune, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.09. This means the shares are trading above this model’s fair value.

Altimmune, Inc. generated EPS of -$1.07 over the past year. Five-year average earnings growth is 3.48%. Wall Street analysts project EPS growth of 8.87% annually over the next five years. The latest quarter delivered EPS of -$0.21. The next quarter is forecast at -$0.23. Next year's EPS is expected at -$12.89. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $12.00. The high target offers 765.05% upside. The low target suggests 315.22% downside. The mean target is $16.20. This offers 460.55% upside. Altimmune, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by -26.68%. The prior quarter beat by -15.62%. Over the last six quarters, Apple has recorded several small beats. These include 2.94% in August 08, 2024.

Altimmune, Inc. (NASDAQ:ALT) closed at $2.85 USD, losing -$0.04 (-1.38%) from the previous close of $2.89. The stock is currently within 5% of its 52-week low $2.80 and $7.73. With a market capitalization of about $251.53 million, Altimmune, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.34). Key stats such as the average daily volume over the past year has been around 4.10 million shares, trading with heavier-than-usual volume. Headquartered in Gaithersburg, MD, Altimmune, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jerome Benedict Durso, the company employs approximately 59 people and listed since May 26, 2017. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

Altimmune, Inc. trades at a P/E ratio of -3.3, slightly below the S&P 500 average, with a price-to-sales ratio of 6221.06 and a price-to-book ratio of 1.29 suggesting the stock is closer to book value. The P/FCF stands at -3.76, also above market averages.

Our AI price prediction model suggests that Altimmune, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.92%, with price expected at $3.35 by May 07, 2026, within a range of $3.18 to $3.52 3-Month Outlook: Projected rise of 17.3%, reaching $3.39 by July 22, 2026, with a range of $3.16 to $3.59. 1-Year Outlook: Projected loss of -46.71%, with price at $1.54 by April 23, 2027, within a range of $0.89 to $2.17.

Altimmune, Inc. (NASDAQ:ALT) shares are up 17.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Altimmune, Inc. trading at a premium to the broader market with a P/E of -3.3. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $22.29, suggesting 671.28% upside. Our AI forecast model points to short-term strength (15.92% over two weeks), a medium-term rise (17.3% over three months), and a longer-term loss (-46.71% over one year), with expected trading ranges indicating moderate volatility.